Shopping Cart
- Remove All
- Your shopping cart is currently empty
CH-0793076, a hexacyclic camptothecin analog, is an active drug and major metabolite of TP300. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein). CH-0793076 inhibits DNA topoisomerase I (IC50: 2.3 μM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | CH-0793076, a hexacyclic camptothecin analog, is an active drug and major metabolite of TP300. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein). CH-0793076 inhibits DNA topoisomerase I (IC50: 2.3 μM). |
Targets&IC50 | Topo I:2.3 μM |
In vitro | CH0793076 (6 days at 37°C) displays antiproliferative activity against PC-6/BCRP and PC-6/pRC cells (IC50: 0.35 and 0.18 nM). |
In vivo | TP300 (1-100 mg/kg; bolus intravenous injection once per week for 3 weeks, for a total of three doses) demonstrates over 50% tumor growth inhibition across all nine models. |
Alias | TP3076 |
Molecular Weight | 458.51 |
Formula | C26H26N4O4 |
Cas No. | 534605-78-2 |
Relative Density. | 1.46 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.